Literature DB >> 32234876

Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer.

Hyun Lee1, Miseon Lee1, Jeong-Han Seo1, Gyungyub Gong1, Hee Jin Lee2.   

Abstract

BACKGROUND/AIM: Neoadjuvant chemotherapy (NAC) can affect tumors and the tumor microenvironment. As changes in tumor-infiltrating lymphocytes (TILs) after NAC and the resulting clinical significance have not been clearly defined, we evaluated both in triple negative breast cancer (TNBC).
MATERIALS AND METHODS: TIL level was histologically analyzed in pre-NAC biopsy and post-NAC operation specimens from 104 TNBC cases with residual invasive carcinoma after NAC.
RESULTS: Forty-three cases (41.3%) showed decreases in TIL level, whereas 29 cases (27.9%) showed increases and no significant changes were found in 32 cases (30.8%). A decrease or increase in TIL levels corresponded to a better disease-free survival (DFS) as compared to unchanged levels. In multivariate analysis, a change in TIL level was an independent prognostic factor for DFS.
CONCLUSION: We identified a prognostic significance of TIL changes after NAC. Assessment of TILs before and after NAC can provide valuable prognostic information for TNBC patients. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Breast cancer; neoadjuvant chemotherapy; tumor-infiltrating lymphocyte

Mesh:

Year:  2020        PMID: 32234876     DOI: 10.21873/anticanres.14142

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.

Authors:  Daniel R Principe; Suneel D Kamath; Murray Korc; Hidayatullah G Munshi
Journal:  Pharmacol Ther       Date:  2022-01-10       Impact factor: 13.400

2.  Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.

Authors:  Victor Sarradin; Amélie Lusque; Thomas Filleron; Florence Dalenc; Camille Franchet
Journal:  Breast Cancer Res       Date:  2021-05-26       Impact factor: 6.466

Review 3.  Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy.

Authors:  Guillermo O Rangel Rivera; Hannah M Knochelmann; Connor J Dwyer; Aubrey S Smith; Megan M Wyatt; Amalia M Rivera-Reyes; Jessica E Thaxton; Chrystal M Paulos
Journal:  Front Immunol       Date:  2021-03-18       Impact factor: 7.561

4.  Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma.

Authors:  Lucas Grecco Hoffmann; Luis Otavio Sarian; José Vassallo; Geisilene Russano de Paiva Silva; Susana Oliveira Botelho Ramalho; Amanda Canato Ferracini; Karina da Silva Araujo; Rodrigo Menezes Jales; Deayra Emyle Figueira; Sophie Derchain
Journal:  Sci Rep       Date:  2021-11-18       Impact factor: 4.379

5.  Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.

Authors:  Cornelia Kolberg-Liedtke; Friedrich Feuerhake; Madlen Garke; Matthias Christgen; Ronald Kates; Eva Maria Grischke; Helmut Forstbauer; Michael Braun; Mathias Warm; John Hackmann; Christoph Uleer; Bahriye Aktas; Claudia Schumacher; Sherko Kuemmel; Rachel Wuerstlein; Monika Graeser; Ulrike Nitz; Hans Kreipe; Oleg Gluz; Nadia Harbeck
Journal:  Breast Cancer Res       Date:  2022-09-02       Impact factor: 8.408

6.  Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model.

Authors:  Sanambar Sadighi; Ramezanali Sharifian; Monireh Kazemimanesh; Ahad Muhammadnejad; Zahra Shahosseini; Saeid Amanpour; Samad Muhammadnejad
Journal:  Iran J Basic Med Sci       Date:  2021-04       Impact factor: 2.699

7.  Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer.

Authors:  Jin Hong; Weiwei Rui; Xiaochun Fei; Xiaosong Chen; Kunwei Shen
Journal:  Cancer Med       Date:  2021-09-25       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.